Short-Duration Blinatumomab for Residual Disease Eradication As a Bridge to Transplant in B-ALL: Pediatric and Adult Outcomes in a Resource-Limited Context

Key Points

• Blinatumomab treatment leads to significant residual disease eradication, improving transplant eligibility.
• In the pediatric cohort, 75% achieved complete remission after a short course of blinatumomab.
• Analysis of patient outcomes revealed higher post-transplant survival rates in those who received pre-transplant blinatumomab.
• Implications include the need for increased access to blinatumomab in resource-limited settings for better patient outcomes.